Table 1 Summary characteristics of CARRAnet initial cohort
Demographic measures | N (%) |
|---|---|
Total participants studied | 1371 |
Female gender | 1024 (75%) |
White/caucasian | 1187 (87%) |
Age at onset of symptoms, mean in years | 7.2 |
Age at baseline visit, mean in years | 11.8 |
Black or African American | 127 (9%) |
Asian | 45 (3%) |
American Indian or Alaska Native | 30 (2%) |
Native Hawaiian or Pacific Islander | 9 (<1%) |
Hispanic ethnicity | 150 (11%) |
Primary rheuamtic diagnosis | Â |
Juveline idiopathic arthritis | 1051 (77%) |
Juveline dematophyositis | 109 (8%) |
Systemic lupus erythematosus | 100 (7%) |
Localized scleroderma | 43 (3%) |
Mixed connective tissue disease | 23 (2%) |
Vasculitis | 23 (2%) |
Systemic sclerosis | 9 (<1%) |
Sarcoidosis | 8 (<1%) |
Juveline primary fibromyalgia syndrome | 6 (<1%) |
Growth parameters | Mean & (Range) |
Weight Z-score | 0.28 (-5.3 – 4.7) |
Height Z-score | -0.14 (-19.7 – 9.4) |
BMI Z-score | 0.38 (-5.0 – 4.1) |
Assessments (scale: best -> worst) | Mean & (Range) |
Physician global assess disease activity (0 – 10) | 1.6 (0 – 10) |
Subject global assess disease activity (0 – 10) | 2.3 (0 – 10) |
Subject pain score (0 – 10) | 2.4 (0 – 10) |
CHAQ (0 – 3) | 0.33 (0 – 3) |
HRQOL – Good, very good, excellent (%) | 96% |
HRQOL – Very poor, poor (%) | 3% |
Family history (first degree relative) of | N (%) |
Psoriasis | 82 (6%) |
Rheumatoid arthritis | 71 (5%) |
Autoimmune throiditis | 62 (5%) |
Fibromyalgia | 61 (4%) |
Juvenile idiopathic arthritis | 55 (4%) |
Diabetes type I | 35 (3%) |
Inflammatory bowel disease | 31 (2%) |
Systemic lupus erthematosus | 28 (2%) |
Spondyloarthritis or ankyl. spondylitis | 16 (1%) |
Multiple sclerosis | 13 (1%) |
Celiac disease | 10 (1%) |
Uveitis | 5 (<1%) |
Medication use | N (%) |
Steroids (ever) | 1010 (74%) |
Steroids (longterm daily, ever) | 644 (47%) |
Steroids (IV pulse, ever) | 212 (15%) |
Steroids (IA, ever) | 529 (39%) |
Biologics (ever) | 560 (41%) |
Biologics (current) | 429 (31%) |
TNF-α Blockers (current) | 338 (25%) |
DMARDs (ever) | 1107 (81%) |
DMARDs (current) | 1021 (75%) |
Methotrexate (current) | 620 (45%) |
NSAIDs (current) | 625 (46%) |
Opioids (current) | 17 (1%) |